GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response

Clinical Immunology

Volumn 137, Issue 1, 2010, Pages 31-40

  Chéramy, Mikael ^a   Skoglund, Camilla ^a   Johansson, Ingela ^a   Ludvigsson, Johnny ^a   Hampe, Christiane S ^b   Casas, Rosaura ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

GAD alum; GAD65; GADA; IgG; IgG subclass; Immunotherapy; T1D; Type 1 diabetes

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBODY; C PEPTIDE; DIAMYD; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; PLACEBO; TETANUS TOXOID ANTIBODY; TYROSINE PHOSPHATASE LIKE PROTEIN 1A 2 ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HORMONE SYNTHESIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ALUM COMPOUNDS; ANTIBODIES; AREA UNDER CURVE; AUTOANTIBODIES; BIOCATALYSIS; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNE SERA; IMMUNITY, HUMORAL; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOTHERAPY, ACTIVE; TETANUS TOXOID; TREATMENT OUTCOME;

EID: 77956614531     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.06.001     Document Type: Article

References (35)

1. Karlsen A.E., Hagopian W.A., Grubin C.E., Dube S., Disteche C.M., Adler D.A., Barmeier H., Mathewes S., Grant F.J., Foster D., et al. Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10. Proc. Natl Acad. Sci. USA 1991, 88:8337-8341.
2. Payton M.A., Hawkes C.J., Christie M.R. Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J. Clin. Invest. 1995, 96:1506-1511.
3. Seissler J., Amann J., Mauch L., Haubruck H., Wolfahrt S., Bieg S., Richter W., Holl R., Heinze E., Northemann W., et al. Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J. Clin. Invest. 1993, 92:1394-1399.
4. Borg H., Marcus C., Sjoblad S., Fernlund P., Sundkvist G. Islet cell antibody frequency differs from that of glutamic acid decarboxylase antibodies/IA2 antibodies after diagnosis of diabetes. Acta Paediatr. 2000, 89:46-51.
5. Savola K., Sabbah E., Kulmala P., Vahasalo P., Ilonen J., Knip M. Autoantibodies associated with type I diabetes mellitus persist after diagnosis in children. Diabetologia 1998, 41:1293-1297.
6. Jensen R., Gilliam L., Torn C., Landin-Olsson M., Palmer J., Akesson K., Kockum I., Lernmark B., Karlsson A.F., Lynch K.F., Breslow N., Lernmark A., Sundkvist G. Islet cell autoantibody levels after the diagnosis of young adult diabetic patients. Diabet. Med. 2007, 24:1221-1228.
7. Hoeldtke R.D., Hampe C.S., Bekris L.M., Hobbs G., Bryner K.D., Lernmark A. Antibodies to GAD65 and peripheral nerve function in the DCCT. J. Neuroimmunol. 2007, 185:182-189.
8. Herold K.C., Gitelman S.E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., Rother K., Diamond B., Harlan D.M., Bluestone J.A. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2years after onset of type 1 diabetes. Diabetes 2005, 54:1763-1769.
9. Schloot N.C., Meierhoff G., Lengyel C., Vandorfi G., Takacs J., Panczel P., Barkai L., Madacsy L., Oroszlan T., Kovacs P., Suto G., Battelino T., Hosszufalusi N., Jermendy G. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007, 23:276-285.
10. Bougneres P.F., Carel J.C., Castano L., Boitard C., Gardin J.P., Landais P., Hors J., Mihatsch M.J., Paillard M., Chaussain J.L., et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J. Med. 1988, 318:663-670.
11. Tisch R., Liblau R.S., Yang X.D., Liblau P., McDevitt H.O. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998, 47:894-899.
12. Agardh C.D., Cilio C.M., Lethagen A., Lynch K., Leslie R.D., Palmer M., Harris R.A., Robertson J.A., Lernmark A. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J. Diab. Complications 2005, 19:238-246.
13. Agardh C.D., Lynch K.F., Palmer M., Link K., Lernmark A. GAD65 vaccination: 5years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 2009, 52:1363-1368.
14. Ludvigsson J., Faresjo M., Hjorth M., Axelsson S., Cheramy M., Pihl M., Vaarala O., Forsander G., Ivarsson S., Johansson C., Lindh A., Nilsson N.O., Aman J., Ortqvist E., Zerhouni P., Casas R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J. Med. 2008, 359:1909-1920.
15. Tian J., Atkinson M.A., Clare-Salzler M., Herschenfeld A., Forsthuber T., Lehmann P.V., Kaufman D.L. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 1996, 183:1561-1567.
16. Lundgren M., Persson U., Larsson P., Magnusson C., Smith C.I., Hammarstrom L., Severinson E. Interleukin 4 induces synthesis of IgE and IgG4 in human B cells. Eur. J. Immunol. 1989, 19:1311-1315.
17. Stavnezer J. Immunoglobulin class switching. Curr. Opin. Immunol. 1996, 8:199-205.
18. King C.L., Nutman T.B. IgE and IgG subclass regulation by IL-4 and IFN-gamma in human helminth infections. Assessment by B cell precursor frequencies. J. Immunol. 1993, 151:458-465.
19. Anon Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J. Med. 2002, 346:1685-1691.
20. Gale E.A., Bingley P.J., Emmett C.L., Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004, 363:925-931.
21. Harrison L.C., Honeyman M.C., Steele C.E., Stone N.L., Sarugeri E., Bonifacio E., Couper J.J., Colman P.G. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diab. Care 2004, 27:2348-2355.
22. Orban T., Farkas K., Jalahej H., Kis J., Treszl A., Falk B., Reijonen H., Wolfsdorf J., Ricker A., Matthews J.B., Tchao N., Sayre P., Bianchine P. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J. Autoimmun. 2010, 34:408-415.
23. Murinson B.B. Stiff-person syndrome. Neurologist 2004, 10:131-137.
24. Wilson R.K., Murinson B.B. Sudden spasms following gradual lordosis-the stiff-person syndrome. Nat. Clin. Pract. Neurol. 2006, 2:455-459. quiz 460.
25. Raju R., Foote J., Banga J.P., Hall T.R., Padoa C.J., Dalakas M.C., Ortqvist E., Hampe C.S. Analysis of GAD65 autoantibodies in stiff-person syndrome patients. J. Immunol. 2005, 175:7755-7762.
26. Levy L.M., Dalakas M.C., Floeter M.K. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann. Intern. Med. 1999, 131:522-530.
27. Grubin C.E., Daniels T., Toivola B., Landin-Olsson M., Hagopian W.A., Li L., Karlsen A.E., Boel E., Michelsen B., Lernmark A. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994, 37:344-350.
28. Murinson B.B., Butler M., Marfurt K., Gleason S., De Camilli P., Solimena M. Markedly elevated GAD antibodies in SPS: effects of age and illness duration. Neurology 2004, 63:2146-2148.
29. Snapper C.M., Mond J.J. Towards a comprehensive view of immunoglobulin class switching. Immunol. Today 1993, 14:15-17.
30. Hillman M., Torn C., Landin-Olsson M. The glutamic acid decarboxylase 65 immunoglobulin G subclass profile differs between adult-onset type 1 diabetes and latent autoimmune diabetes in adults (LADA) up to 3years after clinical onset. Clin. Exp. Immunol. 2009, 157:255-260.
31. Ronkainen M.S., Hoppu S., Korhonen S., Simell S., Veijola R., Ilonen J., Simell O., Knip M. Early epitope- and isotype-specific humoral immune responses to GAD65 in young children with genetic susceptibility to type 1 diabetes. Eur. J. Endocrinol. 2006, 155:633-642.
32. Hillman M., Torn C., Thorgeirsson H., Landin-Olsson M. IgG4-subclass of glutamic acid decarboxylase antibody is more frequent in latent autoimmune diabetes in adults than in type 1 diabetes. Diabetologia 2004, 47:1984-1989.
33. Skyler J.S., Krischer J.P., Wolfsdorf J., Cowie C., Palmer J.P., Greenbaum C., Cuthbertson D., Rafkin-Mervis L.E., Chase H.P., Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diab. Care 2005, 28:1068-1076.
34. Jensen R.A., Gilliam L.K., Torn C., Landin-Olsson M., Karlsson F.A., Palmer J.P., Kockum I., Akesson K., Lernmark B., Lynch K., Breslow N., Lernmark A. Multiple factors affect the loss of measurable C-peptide over 6years in newly diagnosed 15- to 35-year-old diabetic subjects. J. Diab. Complications 2007, 21:205-213.
35. Tian J., Kaufman D.L. Antigen-based therapy for the treatment of type 1 diabetes. Diabetes 2009, 58:1939-1946.